Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trichlorethanol SCHEMBL325071 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL7261325 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL291748 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL759616 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL1436780 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL16162174 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL4450822 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL88329 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL762332 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL6898269 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181196-B2 | Pharmaceutical compounds | KEMOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| EP-2789619-A1 | Pharmaceutical compounds wiht angiogenesis inbhibitory activity | Kemotech S.r.l. (IT) | 2014-10-15 | — | — | EP | disclosed |
| EP-0645379-B1 | Benzoylacetylene derivatives | MITSUBISHI CHEM CORP (JP) | 1999-03-17 | — | — | EP | disclosed |
| US-5240924-A | Dipeptide hypotensives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| CN-1032786-A | N-acyl amino acid derivative and uses thereof | BANYU PHARMA CO LTD (JP) | 1989-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | CYP3A43, CYP2D6, CYP2C9 | LMNA 2488/4885TDP1 3972/4885TP53 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.